Argenx SE Achieves Major Milestone with CHMP’s Positive Opinion for CIDP Treatment VYVGART
Argenx SE’s treatment VYVGART has received a positive opinion from the European CHMP, paving the way for potential approval and marking a significant milestone in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
3 minutes to read